VFA
ACOR

Virtus Fund Advisers’s Acorda Therapeutics ACOR Stock Holding History

Virtus Fund Advisers’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$991K Buy
+385
New +$1.09M 0.01% 288
2014
Q3 		– Sell
-30
Closed -$120K – 2081
2014
Q2 		$120K Buy
+30
New +$122K ﹤0.01% 1261

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus Fund Advisers's ACOR Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Acorda Therapeutics (ACOR) in Q4 2017: 385 shares worth $991K. The stake represents 0.01% of the portfolio and ranks #288 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ACOR as recently as Q2 2014.

Virtus Fund Advisers first reported a position in ACOR in Q2 2014 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

  • Virtus Fund Advisers held 385 shares of Acorda Therapeutics worth $991K as of Q4 2017.
  • Acorda Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Acorda Therapeutics made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #288 holding.
  • Virtus Fund Advisers first reported a position in Acorda Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.